Mevacor Daily OTC Switch Rejected Based On Patient Inability To Self Select
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA joint committee finds that current system does not ensure appropriate patient self-selection for cholesterol-lowering therapy. Committee votes 20-3 against OTC marketing for Mevacor Daily. Behind-the-counter strategy for pharmacy urged.